CN Patent

CN120501712A — 片剂组合物

Assigned to Les Laboratoires Servier SAS · Expires 2025-08-19 · 1y expired

What this patent protects

本文提供了片剂组合物。本文还提供了包含2‑甲基‑1‑[(4‑[6‑(三氟甲基)吡啶‑2‑基]‑6‑{[2‑(三氟甲基)吡啶‑4‑基]氨基}‑1，3，5‑三嗪‑2‑基)氨基]丙‑2‑醇或其药学上可接受的盐的片剂。

USPTO Abstract

本文提供了片剂组合物。本文还提供了包含2‑甲基‑1‑[(4‑[6‑(三氟甲基)吡啶‑2‑基]‑6‑{[2‑(三氟甲基)吡啶‑4‑基]氨基}‑1，3，5‑三嗪‑2‑基)氨基]丙‑2‑醇或其药学上可接受的盐的片剂。

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: CN120501712A
Jurisdiction: CN
Classification: —
Expires: 2025-08-19
Drug substance claim: No
Drug product claim: No
Assignee: Les Laboratoires Servier SAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.